Qiagen reports Q3 adjusted EPS 61c, consensus 59c

Reports Q3 revenue $533M, consensus $525.91M. “Qiagen (QGEN) continues to deliver in a challenging environment, with another quarter of results above our outlook and among the fastest growth rates in the industry. We are pleased with the sustained growth from QIAstat-Dx and QuantiFERON, along with solid momentum in Sample technologies as we prepare to launch three new instruments. The acquisition of Parse Biosciences is an excellent strategic fit, strengthening our leadership in Sample technologies by providing access to the high-growth single-cell market and the ability to offer solutions to drive large-scale AI-driven biology. It reflects our commitment to invest in innovation offering accretive returns and expand our addressable markets. As we update our targets for 2025, we are moving ahead on our ambitions to deliver solid profitable growth,” said CEO Thierry Bernard.